

**Cigna - Medicare Advantage**  
**Medical Oncology Code List**

**\*\*\*Please note: This list is constantly evolving as new drugs come to market and are approved by the FDA as well as with any HCPC**

- *For Medical Oncology program – Pepcid/Famotidine does not require precertification when billed under J3490*
- *Nivestym (filgrastim-aafi) and Zarxio (filgrastim-sndz) are preferred agents and do not require precertification*

Effective Date: 07/01/25

| Description                                          | Alt Descriptions         | HCPCs Code | Program                  | Drug Class              | Administration Technique | Medicare Category: B / D / S | Cigna Medicare Advantage | Drug Comments   |
|------------------------------------------------------|--------------------------|------------|--------------------------|-------------------------|--------------------------|------------------------------|--------------------------|-----------------|
| 5-Fluorouracil- Injection                            | 5FU, Adrucil             | J9190      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S (P)                        | Y                        |                 |
| Ado-Trastuzumab Emtansine                            | Kadcyla                  | J9354      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Aldesleukin                                          | Proleukin, Interleukin-2 | J9015      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Amivantamab-vmjw                                     | Rybrevant                | J9061      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Anakinra                                             | Kineret                  | J3590      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               |                              | Y                        |                 |
| Aprepitant                                           | Cinvanti                 | J0185      | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE               | S                            | Y                        |                 |
| Arsenic Trioxide                                     | Trisenox                 | J9017      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Asparaginase                                         | Erwinaze                 | J9019      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Asparaginase erwinia chrysanthemi (recombinant)-rywn | Rylaze                   | J9021      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Atezolizumab                                         | Tecentriq                | J9022      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Atezolizumab and Hyaluronidase-tqjs                  | Tecentriq Hybreza        | J9024      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Avelumab                                             | Bavencio                 | J9023      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Azacitidine                                          | Vidaza                   | J9025      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Azacitidine - oral                                   | Onureg                   | J8999      | Medical Oncology - CHEMO | Primary                 | ORAL                     | B                            | Y                        | Medicare Part B |
| BCG                                                  | TheraCys, Tice           | J9030      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Belinostat                                           | Beleodaq                 | J9032      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Bendamustine HCL                                     | Belrapzo                 | J9036      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Bendamustine HCL                                     | Bendeka                  | J9034      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Bendamustine HCL                                     | Treanda                  | J9033      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Bendamustine HCL (vivimusta)                         |                          | J9056      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |
| Bevacizumab                                          | Avastin                  | J9035      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                 |

Effective Date: 07/01/25

| Description                           | Alt Descriptions | HCPCs Code | Program                  | Drug Class           | Administration Technique | Medicare Category: B / D / S | Cigna Medicare Advantage | Drug Comments                                                                                                  |
|---------------------------------------|------------------|------------|--------------------------|----------------------|--------------------------|------------------------------|--------------------------|----------------------------------------------------------------------------------------------------------------|
| Bevacizumab (Radiation Necrosis)      | Avastin          | J9035      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | Supportive use of Avastin to treat Radiation Induced Necrosis of the CNS                                       |
| Bevacizumab-adcd                      | Vegzelma         | Q5129      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                                |
| Bevacizumab-adcd                      | Vegzelma         | Q5129      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | Supportive use of Vegzelma to treat Radiation Induced Necrosis of the CNS                                      |
| Bevacizumab-awwb                      | Mvasi            | Q5107      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                                |
| Bevacizumab-awwb (Radiation Necrosis) | Mvasi            | Q5107      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | Supportive use of Mvasi to treat Radiation Induced Necrosis of the CNS                                         |
| Bevacizumab-bvzr                      | Zirabev          | Q5118      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | Supportive use of Zirabev to treat Radiation Induced Necrosis of the CNS                                       |
| Bevacizumab-bvzr                      | Zirabev          | Q5118      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                                |
| Bevacizumab-maly                      | AlymSYS          | Q5126      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                                |
| Bevacizumab-maly (Radiation Necrosis) | AlymSYS          | Q5126      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | Supportive use of AlymSYS to treat Radiation Induced Necrosis of the CNS                                       |
| Bevacizumab-nwgd                      | Jobevne          | C9399      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar for Bevacizumab, effective: 05/15/25                                                    |
| Bevacizumab-nwgd                      | Jobevne          | J3490      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar for Bevacizumab, effective: 05/15/25                                                    |
| Bevacizumab-nwgd                      | Jobevne          | J3590      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar for Bevacizumab, effective: 05/15/25                                                    |
| Bevacizumab-nwgd                      | Jobevne          | J9999      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar for Bevacizumab, effective: 05/15/25                                                    |
| Bevacizumab-nwgd                      | Jobevne          | C9399      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | New supportive biosimilar for Bevacizumab, to treat Radiation Induced Necrosis of the CNS, effective: 05/15/25 |
| Bevacizumab-nwgd                      | Jobevne          | J3490      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | New supportive biosimilar for Bevacizumab, to treat Radiation Induced Necrosis of the CNS, effective: 05/15/25 |
| Bevacizumab-nwgd                      | Jobevne          | J3590      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | New supportive biosimilar for Bevacizumab, to treat Radiation Induced Necrosis of the CNS, effective: 05/15/25 |
| Bevacizumab-nwgd                      | Jobevne          | J9999      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | New supportive biosimilar for Bevacizumab, to treat Radiation Induced Necrosis of the CNS, effective: 05/15/25 |
| Bevacizumab-tnjn                      | Avzivi           | C9399      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                                |
| Bevacizumab-tnjn                      | Avzivi           | C9399      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | Supportive use of Avzivi to treat Radiation Induced Necrosis of the CNS.                                       |
| Bevacizumab-tnjn                      | Avzivi           | J3490      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                                |
| Bevacizumab-tnjn                      | Avzivi           | J3490      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | Supportive use of Avzivi to treat Radiation Induced Necrosis of the CNS.                                       |

Effective Date: 07/01/25

| Description                        | Alt Descriptions | HCPCs Code | Program                  | Drug Class           | Administration Technique | Medicare Category: B / D / S | Cigna Medicare Advantage | Drug Comments                                                                            |
|------------------------------------|------------------|------------|--------------------------|----------------------|--------------------------|------------------------------|--------------------------|------------------------------------------------------------------------------------------|
| Bevacizumab-tjnj                   | Avzivi           | J3590      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                          |
| Bevacizumab-tjnj                   | Avzivi           | J3590      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | Supportive use of Avzivi to treat Radiation Induced Necrosis of the CNS.                 |
| Bevacizumab-tjnj                   | Avzivi           | J9999      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                          |
| Bevacizumab-tjnj                   | Avzivi           | J9999      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | Supportive use of Avzivi to treat Radiation Induced Necrosis of the CNS.                 |
| Bleomycin                          | Blenoxane        | J9040      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S (P)                        | Y                        |                                                                                          |
| Blinatumomab                       | Blincyto         | J9039      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S (P)                        | Y                        |                                                                                          |
| Bortezomib                         | Velcade          | J9041      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Bortezomib (boruzu)                |                  | J9054      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Bortezomib (hospira)               |                  | J9049      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Bortezomib (maia)                  |                  | J9051      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Brentuximab Vedotin                | Adcetris         | J9042      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Burosumab-twza                     | Crysvita         | J0584      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                          |
| Cabazitaxel                        | Jevtana          | J9043      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Cabazitaxel (sandoz)               |                  | J9064      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Calaspargase pegol-mknl            | Asparlas         | J9118      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Capecitabine - oral                | Xeloda (50 mg)   | J8522      | Medical Oncology - CHEMO | Primary              | ORAL                     | B                            | Y                        | Medicare Part B                                                                          |
| Carboplatin                        | Paraplatin       | J9045      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Carfilzomib                        | Kyprolis         | J9047      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Carmustine                         | BiCNU, BCNU      | J9050      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Carmustine (accord)                |                  | J9052      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Cemiplimab-rwlc                    | Libtayo          | J9119      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Cetuximab                          | Erbix            | J9055      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Chlorambucil - oral                | Leukeran         | J8999      | Medical Oncology - CHEMO | Primary              | ORAL                     | B                            | Y                        | Medicare Part B                                                                          |
| Chlorambucil - oral                | Leukeran         | S0172      | Medical Oncology - CHEMO | Primary              | ORAL                     | B                            | Y                        | Medicare Part B                                                                          |
| Cisplatin                          | Platinol         | J9060      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Cladribine                         | Leustatin        | J9065      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S (P)                        | Y                        |                                                                                          |
| Clofarabine                        | Clolar           | J9027      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |
| Cosibelimab-ipdl                   | Unloxcyt         | J9275      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        | New permanent HCPC Code: J9275 will replace NOC Code: C9399 & J9999, effective: 07/01/25 |
| Cyclophosphamide - inj (auromedic) |                  | J9071      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                          |

Effective Date: 07/01/25

| Description                                   | Alt Descriptions      | HCPCs Code | Program                  | Drug Class           | Administration Technique | Medicare Category: B / D / S | Cigna Medicare Advantage | Drug Comments                                                                                                   |
|-----------------------------------------------|-----------------------|------------|--------------------------|----------------------|--------------------------|------------------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------|
| Cyclophosphamide - inj (baxter)               |                       | J9076      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Cyclophosphamide - inj (dr. reddy's)          |                       | J9072      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Cyclophosphamide - inj (ingenus)              |                       | J9073      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Cyclophosphamide - inj (sandoz)               |                       | J9074      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Cyclophosphamide Inj, not otherwise specified |                       | J9075      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Cytarabine                                    | Ara-C                 | J9100      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S (P)                        | Y                        |                                                                                                                 |
| Dacarbazine                                   | DTIC-Dome             | J9130      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Dactinomycin                                  | Cosmegen, Actinomycin | J9120      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Daratumumab                                   | Darzalex              | J9145      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Daratumumab and hyaluronidase-fihj            | Darzalex Faspro       | J9144      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Darbepoetin alfa                              | Aranesp               | J0881      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S (ESA)                      | Y                        |                                                                                                                 |
| Datopotamab deruxtecan-dlnk                   | Datroway              | C9174      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        | C9174 will replace NOC Code: C9399 for Datroway, effective: 07/01/25                                            |
| Datopotamab deruxtecan-dlnk                   | Datroway              | J9999      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Daunorubicin                                  | Cerubidine            | J9150      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Decitabine                                    | Dacogen               | J0894      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Decitabine (sun pharma)                       |                       | J0893      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Degarelix                                     | Firmagon              | J9155      | Medical Oncology - CHEMO | Primary - LHRH       | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Denileukin Diftitox-cxdl                      | Lymphir               | J9161      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | B                            | Y                        |                                                                                                                 |
| Denosumab                                     | Xgeva, Prolia         | J0897      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Denosumab                                     | Xgeva, Prolia         | J0897      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        | Primary chemotherapy drug for the use of Xgeva to treat Giant Cell Tumor.                                       |
| Denosumab-bbdz                                | Wyost, Jubbonti       | Q5136      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Denosumab-bbdz                                | Wyost, Jubbonti       | Q5136      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | Primary chemotherapy drug for the use of Wyost, to treat Giant Cell Tumor.                                      |
| Denosumab-bmwo                                | Osenvelt, Stoboclo    | C9399      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Denosumab-bmwo                                | Osenvelt, Stoboclo    | C9399      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar chemotherapy drug for the use of Osenvelt to treat Giant Cell Tumor, effective: 04/10/25 |
| Denosumab-bmwo                                | Osenvelt, Stoboclo    | J3490      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Denosumab-bmwo                                | Osenvelt, Stoboclo    | J3490      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar chemotherapy drug for the use of Osenvelt to treat Giant Cell Tumor, effective: 04/10/25 |
| Denosumab-bmwo                                | Osenvelt, Stoboclo    | J3590      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                                 |

Effective Date: 07/01/25

| Description    | Alt Descriptions    | HCPCs Code | Program                  | Drug Class           | Administration Technique | Medicare Category: B / D / S | Cigna Medicare Advantage | Drug Comments                                                                                                   |
|----------------|---------------------|------------|--------------------------|----------------------|--------------------------|------------------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------|
| Denosumab-bmwo | Osenvelt, Stoboclo  | J3590      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar chemotherapy drug for the use of Osenvelt to treat Giant Cell Tumor, effective: 04/10/25 |
| Denosumab-bmwo | Osenvelt, Stoboclo  | J9999      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Denosumab-bmwo | Osenvelt, Stoboclo  | J9999      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar chemotherapy drug for the use of Osenvelt to treat Giant Cell Tumor, effective: 04/10/25 |
| Denosumab-bnht | Bomyntra, Conexence | C9399      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | New supportive biosimilar for Prolia effective: 04/10/25                                                        |
| Denosumab-bnht | Bomyntra, Conexence | C9399      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar chemotherapy drug for the use of Bomyntra to treat Giant Cell Tumor, effective: 04/10/25 |
| Denosumab-bnht | Bomyntra, Conexence | J3490      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | New supportive biosimilar for Prolia effective: 04/10/25                                                        |
| Denosumab-bnht | Bomyntra, Conexence | J3490      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar chemotherapy drug for the use of Bomyntra to treat Giant Cell Tumor, effective: 04/10/25 |
| Denosumab-bnht | Bomyntra, Conexence | J3590      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | New supportive biosimilar for Prolia effective: 04/10/25                                                        |
| Denosumab-bnht | Bomyntra, Conexence | J3590      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar chemotherapy drug for the use of Bomyntra to treat Giant Cell Tumor, effective: 04/10/25 |
| Denosumab-bnht | Bomyntra, Conexence | J9999      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | New supportive biosimilar for Prolia effective: 04/10/25                                                        |
| Denosumab-bnht | Bomyntra, Conexence | J9999      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar chemotherapy drug for the use of Bomyntra to treat Giant Cell Tumor, effective: 04/10/25 |
| Denosumab-dssb | Xbryk, Ospomyv      | C9399      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | Primary biosimilar chemotherapy drug for the use of Xgeva to treat Giant Cell Tumor.                            |
| Denosumab-dssb | Xbryk, Ospomyv      | C9399      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Denosumab-dssb | Xbryk, Ospomyv      | J3490      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | Primary biosimilar chemotherapy drug for the use of Xgeva to treat Giant Cell Tumor.                            |
| Denosumab-dssb | Xbryk, Ospomyv      | J3490      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Denosumab-dssb | Xbryk, Ospomyv      | J3590      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | Primary biosimilar chemotherapy drug for the use of Xgeva to treat Giant Cell Tumor.                            |
| Denosumab-dssb | Xbryk, Ospomyv      | J3590      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Denosumab-dssb | Xbryk, Ospomyv      | J9999      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | Primary biosimilar chemotherapy drug for the use of Xgeva to treat Giant Cell Tumor.                            |
| Denosumab-dssb | Xbryk, Ospomyv      | J9999      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Dinutuximab    | Unituxin            | C9399      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |
| Dinutuximab    | Unituxin            | J9999      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                                 |

Effective Date: 07/01/25

| Description                     | Alt Descriptions                                           | HCPCs Code | Program                  | Drug Class              | Administration Technique | Medicare Category: B / D / S | Cigna Medicare Advantage | Drug Comments                                                  |
|---------------------------------|------------------------------------------------------------|------------|--------------------------|-------------------------|--------------------------|------------------------------|--------------------------|----------------------------------------------------------------|
| Docetaxel                       | Taxotere                                                   | J9171      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Docetaxel (beizray)             |                                                            | J9174      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        | New manufacture code: J9174 for Docetaxel, effective: 07/01/25 |
| Docetaxel (docivyx)             |                                                            | J9172      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Dostarlimab-gxly                | Jemperli                                                   | J9272      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Doxorubicin HCL                 | Adriamycin                                                 | J9000      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Doxorubicin HCL (liposomal)     | Doxil, Doxorubicin HCL (Liposomal) not otherwise specified | Q2050      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Durvalumab                      | Imfinzi                                                    | J9173      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Efbemalenograstim alfa-vuxw     | Ryzneuta                                                   | J9361      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                                |
| Eflapegrastim-xnst              | Rolvedon                                                   | J1449      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                                |
| Elotuzumab                      | Empliciti                                                  | J9176      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S (P)                        | Y                        |                                                                |
| Elranatamab-bcmm                | Elrexlio                                                   | J1323      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Enfortumab vedotin-ejfv         | Padcev                                                     | J9177      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Epcoritamab-bysp                | Epkinly                                                    | J9321      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Epirubicin                      | Ellence                                                    | J9178      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Epoetin alfa                    | Epogen, Procrit                                            | J0885      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S (ESA)                      | Y                        |                                                                |
| Epoetin alfa-epbx               | Retacrit                                                   | Q5106      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S (ESA)                      | Y                        |                                                                |
| Eribulin mesylate               | Halaven                                                    | J9179      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Etoposide - inj                 | Toposar, VePesid, Etopophos                                | J9181      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Etoposide - oral                | Toposar                                                    | J8560      | Medical Oncology - CHEMO | Primary                 | ORAL                     | B                            | Y                        | Medicare Part B                                                |
| Fam-trastuzumab deruxtecan-nxki | Enhertu                                                    | J9358      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Filgrastim                      | Neupogen                                                   | J1442      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                                |
| Filgrastim-aafi                 | Nivestym                                                   | Q5110      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                                |
| Filgrastim-ayow                 | Releuko                                                    | Q5125      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                                |
| Filgrastim-sndz                 | Zarxio                                                     | Q5101      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                                |
| Filgrastim-txid                 | Nypozi                                                     | Q5148      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                                |
| Floxuridine                     | FUDR                                                       | J9200      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S (P)                        | Y                        |                                                                |
| Fludarabine Phosphate           | Fludara, Oforta                                            | J9185      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                                |
| Fosaprepitant                   | Emend                                                      | J1453      | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE               | S                            | Y                        |                                                                |
| Fosaprepitant (focinvez)        |                                                            | J1434      | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE               | S                            | Y                        |                                                                |
| Fosaprepitant (teva)            |                                                            | J1456      | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE               | S                            | Y                        |                                                                |

Effective Date: 07/01/25

| Description                                                      | Alt Descriptions                                  | HCPCs Code | Program                  | Drug Class              | Administration Technique | Medicare Category: B / D / S | Cigna Medicare Advantage | Drug Comments |
|------------------------------------------------------------------|---------------------------------------------------|------------|--------------------------|-------------------------|--------------------------|------------------------------|--------------------------|---------------|
| Fosnetupitant/Palonosetron                                       | Akynzeo                                           | J1454      | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE               | S                            | Y                        |               |
| Fulvestrant                                                      | Faslodex                                          | J9395      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Fulvestrant (fresenius kabi)                                     |                                                   | J9394      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Gemcitabine                                                      | Gemzar                                            | J9201      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Gemcitabine Hydrochloride (accord)                               |                                                   | J9196      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Gemtuzumab Ozogamicin                                            | Mylotarg                                          | J9203      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Glofitamab-gxbm                                                  | Columnvi                                          | J9286      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Goserelin acetate implant                                        | Zoladex                                           | J9202      | Medical Oncology - CHEMO | Primary - LHRH          | INJECTABLE               | S                            | Y                        |               |
| Granisetron - subcutaneous                                       | Sustol                                            | J1627      | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE               | S                            | Y                        |               |
| Idarubicin HCL - inj                                             | Idamycin                                          | J9211      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Ifosfamide                                                       | Ifex, Mitoxana                                    | J9208      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Imetelstat                                                       | Rytelo                                            | J0870      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Inotuzumab Ozogamicin                                            | Besponsa                                          | J9229      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Interferon, gamma-1b                                             | Actimmune                                         | J9216      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Ipilimumab                                                       | Yervoy                                            | J9228      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Irinotecan                                                       | Camptosar                                         | J9206      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Irinotecan Liposome                                              | Onivyde                                           | J9205      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Isatuximab-irfc                                                  | Sarclisa                                          | J9227      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Ixabepilone                                                      | Ixempra                                           | J9207      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Lanreotide (Cipla) (J1932)                                       |                                                   | J1932      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Lanreotide (J1930)                                               | Somatuline Depot                                  | J1930      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Leucovorin - inj                                                 | Leucovorin Calcium                                | J0640      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Leuprolide Acetate (cipla)                                       |                                                   | J1954      | Medical Oncology - CHEMO | Primary - LHRH          | INJECTABLE               | S                            | Y                        |               |
| Leuprolide Acetate (J1950: 3.75mg)                               | Eligard, Lupron Depot, Lupron, Leuprolide Acetate | J1950      | Medical Oncology - CHEMO | Primary - LHRH          | INJECTABLE               | S                            | Y                        |               |
| Leuprolide Acetate (J9217: 7.5mg)                                | Eligard, Lupron Depot, Lupron, Leuprolide Acetate | J9217      | Medical Oncology - CHEMO | Primary - LHRH          | INJECTABLE               | S                            | Y                        |               |
| Leuprolide Acetate (J9218: 1mg)                                  | Lupron                                            | J9218      | Medical Oncology - CHEMO | Primary - LHRH          | INJECTABLE               | S                            | Y                        |               |
| Leuprolide Mesylate                                              | Camcevi                                           | J1952      | Medical Oncology - CHEMO | Primary - LHRH          | INJECTABLE               | S                            | Y                        |               |
| Levoleucovorin                                                   | Fusilev                                           | J0641      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Levoleucovorin                                                   | Khapzory                                          | J0642      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |
| Liposome-encapsulated combination of Daunorubicin and Cytarabine | Vyxeos                                            | J9153      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |               |

Effective Date: 07/01/25

| Description                       | Alt Descriptions | HCPCs Code | Program                  | Drug Class | Administration Technique | Medicare Category: B / D / S | Cigna Medicare Advantage | Drug Comments                                                                            |
|-----------------------------------|------------------|------------|--------------------------|------------|--------------------------|------------------------------|--------------------------|------------------------------------------------------------------------------------------|
| Loncastuximab tesirine-lpyl       | Zynlonta         | J9359      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Lurbinectedin                     | Zepzelca         | J9223      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Luspatercept-aamt                 | Reblozyl         | J0896      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Metgetuximab-cmkb                 | Margenza         | J9353      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Melphalan (apotex)                | Ivra             | J9249      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Melphalan (hepzato)               |                  | J9248      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Melphalan HCL - inj               | Evomela          | J9246      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Melphalan HCL - NOS inj           | Alkeran          | J9245      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Mesna                             | Mesnex           | J9209      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Methotrexate (accord)             |                  | J9255      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Methotrexate Sodium, 50mg         |                  | J9260      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Mirvetuximab Soravtansine-gynx    | Elahere          | J9063      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Mitomycin                         | Jelmyto          | J9281      | Medical Oncology - CHEMO | Primary    | PYELOCALYCEAL            | B                            | Y                        | Medicare Part B                                                                          |
| Mitomycin                         | Mutamycin        | J9280      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Mitoxantrone HCL                  | Novantrone       | J9293      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Mogamulizumab-kpkc                | Poteligeo        | J9204      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Mosunetuzumab-axgb                | Lunsumio         | J9350      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | B                            | Y                        |                                                                                          |
| Nadofaragen Firdenovec-vncg       | Adstiladrin      | J9029      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | B                            | Y                        |                                                                                          |
| Naxitamab-ggqk                    | Danyelza         | J9348      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Necitumumab                       | Portrazza        | J9295      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S (P)                        | Y                        |                                                                                          |
| Nelarabine                        | Arranon          | J9261      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Nivolumab                         | Opdivo           | J9299      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Nivolumab and Relatlimab-rmbw     | Opdualag         | J9298      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Nivolumab and Hyaluronidase-nvhy  | Opdivo Quantig   | J9289      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        | New permanent HCPC Code: J9289 will replace NOC Code: C9399 & J9999, effective: 07/01/25 |
| Nogapendekin alfa inbakicept-pmln | Anktiva          | J9028      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | B                            | Y                        |                                                                                          |
| Obinutuzumab                      | Gazyva           | J9301      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Octreotide, depot                 | Sandostatin LAR  | J2353      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Octreotide, depot                 | Sandostatin LAR  | J2353      | Medical Oncology - SPORT | Supportive | INJECTABLE               | S                            | Y                        |                                                                                          |
| Octreotide, non-depot             | Sandostatin      | J2354      | Medical Oncology - CHEMO | Primary    | INJECTABLE               | S                            | Y                        |                                                                                          |
| Octreotide, non-depot             | Sandostatin      | J2354      | Medical Oncology - SPORT | Supportive | INJECTABLE               | S                            | Y                        |                                                                                          |

Effective Date: 07/01/25

| Description                                | Alt Descriptions                           | HCPCs Code | Program                  | Drug Class              | Administration Technique | Medicare Category: B / D / S | Cigna Medicare Advantage | Drug Comments                                      |
|--------------------------------------------|--------------------------------------------|------------|--------------------------|-------------------------|--------------------------|------------------------------|--------------------------|----------------------------------------------------|
| Ofatumumab                                 | Arzerra                                    | J9302      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S (P)                        | Y                        |                                                    |
| Oxaliplatin                                | Eloxatin                                   | J9263      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Paclitaxel                                 | Nov-Onxol, Taxol                           | J9267      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Paclitaxel (albumin-bound)                 | Abraxane                                   | J9264      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Palonosetron                               | Aloxi                                      | J2469      | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE               | S                            | Y                        |                                                    |
| Palonosetron Hydrochloride (posfrea)       |                                            | J2468      | Medical Oncology - SPORT | Supportive - Antiemetic | INJECTABLE               | S                            | Y                        |                                                    |
| Pamidronate Disodium                       | Aredia                                     | J2430      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                    |
| Panitumumab                                | Vectibix                                   | J9303      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S (P)                        | Y                        |                                                    |
| Pegaspargase                               | Oncaspar                                   | J9266      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Pegfilgrastim, excludes biosimilar, 0.5 mg | Neulasta                                   | J2506      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                    |
| Pegfilgrastim-apgf                         | Nyvepria                                   | Q5122      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                    |
| Pegfilgrastim-bmez                         | Ziextenzo                                  | Q5120      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                    |
| Pegfilgrastim-cbqv                         | Udenyca                                    | Q5111      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                    |
| Pegfilgrastim-fpgk                         | Stimufend                                  | Q5127      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                    |
| Pegfilgrastim-jmdb                         | Fulphila                                   | Q5108      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                    |
| Pegfilgrastim-pbbk                         | Fynetra                                    | Q5130      | Medical Oncology - SPORT | Supportive              | INJECTABLE               | S                            | Y                        |                                                    |
| Peginterferon, alfa-2a                     | Pegasys                                    | J3590      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Peginterferon, alfa-2a                     | Pegasys                                    | S0145      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Pembrolizumab                              | Keytruda                                   | J9271      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Pemetrexed                                 | Alimta, Pemetrexed not otherwise specified | J9305      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Pemetrexed                                 | Ditromethamine                             | J9323      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Pemetrexed                                 | Pemfexy                                    | J9304      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Pemetrexed (accord)                        |                                            | J9296      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Pemetrexed (avyxa)                         | Axtle                                      | J9292      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Pemetrexed (bluepoint)                     |                                            | J9322      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Pemetrexed (hospira)                       |                                            | J9294      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Pemetrexed (pemrydi rtu)                   |                                            | J9324      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Pemetrexed (sandoz)                        |                                            | J9297      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Pemetrexed (teva)                          |                                            | J9314      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        |                                                    |
| Penpulimab-kcqx                            |                                            | C9399      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        | New primary chemotherapy drug, effective: 05/05/25 |
| Penpulimab-kcqx                            |                                            | J3490      | Medical Oncology - CHEMO | Primary                 | INJECTABLE               | S                            | Y                        | New primary chemotherapy drug, effective: 05/05/25 |

Effective Date: 07/01/25

| Description                                                                 | Alt Descriptions | HCPCs Code | Program                  | Drug Class           | Administration Technique | Medicare Category: B / D / S | Cigna Medicare Advantage | Drug Comments                                      |
|-----------------------------------------------------------------------------|------------------|------------|--------------------------|----------------------|--------------------------|------------------------------|--------------------------|----------------------------------------------------|
| Penpulimab-kcqx                                                             |                  | J3590      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        | New primary chemotherapy drug, effective: 05/05/25 |
| Penpulimab-kcqx                                                             |                  | J9999      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        | New primary chemotherapy drug, effective: 05/05/25 |
| Pentostatin                                                                 | Nipent           | J9268      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Pertuzumab                                                                  | Perjeta          | J9306      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Pertuzumab / trastuzumab / hyaluronidase-zzxf                               | Phesgo           | J9316      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Polatuzumab vedotin-piiq                                                    | Polivy           | J9309      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Porfimer Sodium                                                             | Photofrin        | J9600      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S (P)                        | Y                        |                                                    |
| Pralatrexate                                                                | Folotylin        | J9307      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Ramucirumab                                                                 | Cyramza          | J9308      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S (P)                        | Y                        |                                                    |
| Retifanlimab-dlwr                                                           | Zynyz            | J9345      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | B                            | Y                        |                                                    |
| Rituximab                                                                   | Rituxan          | J9312      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Rituximab and Hyaluronidase Human                                           | Rituxan Hycela   | J9311      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Rituximab-abbs                                                              | Truxima          | Q5115      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                    |
| Rituximab-arrx                                                              | Riabni           | Q5123      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                    |
| Rituximab-pvvr                                                              | Ruxience         | Q5119      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                    |
| Romidepsin (lyophilized)                                                    | Istodax          | J9319      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Romidepsin (non-lyophilized)                                                |                  | J9318      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Romiplostim                                                                 | Nplate           | J2802      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                    |
| Romiplostim                                                                 | Nplate           | J2802      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Ropeginterferon alfa-2b-njft                                                | Besremi          | C9399      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Ropeginterferon alfa-2b-njft                                                | Besremi          | J9999      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Sacituzumab govitecan-hziy                                                  | Trodelvy         | J9317      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Sargramostim                                                                | Leukine          | J2820      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                    |
| Siltuximab                                                                  | Sylvant          | J2860      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Sipuleucel-T                                                                | Provenge         | Q2043      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | B                            | Y                        |                                                    |
| Sirolimus protein-bound particles for injectable suspension (albumin bound) | Fyarro           | J9331      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Sodium Thiosulfate Injection                                                | Pedmark          | J0208      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | B                            | Y                        |                                                    |
| Sodium Thiosulfate injection (hope)                                         |                  | J0209      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | B                            | Y                        |                                                    |
| Streptozocin                                                                | Zanosar          | J9320      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |
| Tafasitamab-cxix                                                            | Monjuvi          | J9349      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                    |

Effective Date: 07/01/25

| Description                                 | Alt Descriptions | HCPCs Code | Program                  | Drug Class           | Administration Technique | Medicare Category: B / D / S | Cigna Medicare Advantage | Drug Comments                                                                                          |
|---------------------------------------------|------------------|------------|--------------------------|----------------------|--------------------------|------------------------------|--------------------------|--------------------------------------------------------------------------------------------------------|
| Tagraxofusp-erzs                            | Elzonris         | J9269      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S (P)                        | Y                        |                                                                                                        |
| Talimogene Laherparepvec                    | Imlygic          | J9325      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Talquetamab-tgvs                            | Talvey           | J3055      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Tarlatamab-dlle                             | Imdeltra         | J9026      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Tbo-filgrastim                              | Granix           | J1447      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Tebentafusp-tebn                            | Kimmtrak         | J9274      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Teclistamab-cqyv                            | Tecvayli         | J9380      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Telisotuzumab vedotin-tllv                  | Emrelis          | C9399      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        | New primary chemotherapy drug, effective: 06/05/25                                                     |
| Telisotuzumab vedotin-tllv                  | Emrelis          | J9999      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        | New primary chemotherapy drug, effective: 06/05/25                                                     |
| Temozolomide - inj                          | Temodar          | J9328      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Temozolomide - oral                         | Temodar          | J8700      | Medical Oncology - CHEMO | Primary              | ORAL                     | B                            | Y                        | Medicare Part B                                                                                        |
| Temsirolimus                                | Torisel          | J9330      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Thiotepa                                    | Tepylute         | J9341      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        | New permanent HCPC Code: J9341 will replace NOC Codes: C9399 & J9999 for Tepylute, effective: 07/01/25 |
| Thiotepa Injection, not otherwise specified |                  | J9342      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        | New permanent HCPC Code: J9342 will replace HCPC Code: J9340 for Thiotepa, effective: 07/01/25         |
| Tislelizumab-jsgr                           | Tevimbra         | J9329      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Tisotumab vedotin-tftv                      | Tivdak           | J9273      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Tocilizumab                                 | Actemra          | J3262      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Tocilizumab                                 | Actemra          | J3262      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Tocilizumab-aazg                            | Tyenne           | Q5135      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Tocilizumab-aazg                            | Tyenne           | Q5135      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Tocilizumab-anoh                            | Avtozma          | C9399      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar for Tocilizumab, effective: 05/15/25                                            |
| Tocilizumab-anoh                            | Avtozma          | J3490      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar for Tocilizumab, effective: 05/15/25                                            |
| Tocilizumab-anoh                            | Avtozma          | J3590      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar for Tocilizumab, effective: 05/15/25                                            |
| Tocilizumab-anoh                            | Avtozma          | J9999      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        | New primary biosimilar for Tocilizumab, effective: 05/15/25                                            |
| Tocilizumab-anoh                            | Avtozma          | C9399      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | New supportive drug, effective: 05/15/25                                                               |
| Tocilizumab-anoh                            | Avtozma          | J3490      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | New supportive drug, effective: 05/15/25                                                               |
| Tocilizumab-anoh                            | Avtozma          | J3590      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | New supportive drug, effective: 05/15/25                                                               |

Effective Date: 07/01/25

| Description                        | Alt Descriptions      | HCPCs Code | Program                  | Drug Class           | Administration Technique | Medicare Category: B / D / S | Cigna Medicare Advantage | Drug Comments                                                                                          |
|------------------------------------|-----------------------|------------|--------------------------|----------------------|--------------------------|------------------------------|--------------------------|--------------------------------------------------------------------------------------------------------|
| Tocilizumab-anoh                   | Avtozma               | J9999      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        | New supportive drug, effective: 05/15/25                                                               |
| Tocilizumab-bavi                   | Tofidence             | Q5133      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Tocilizumab-bavi                   | Tofidence             | Q5133      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Topotecan - inj                    | Hycamtin              | J9351      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Topotecan - oral                   | Hycamtin              | J8705      | Medical Oncology - CHEMO | Primary              | ORAL                     | B                            | Y                        | Medicare Part B                                                                                        |
| Toripalimab-tpzi                   | Loqtorzi              | J3263      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Trabectedin                        | Yondelis              | J9352      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Trastuzumab                        | Herceptin             | J9355      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Trastuzumab and hyaluronidase-oysk | Herceptin Hylecta     | J9356      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Trastuzumab-anns                   | Kanjinti              | Q5117      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Trastuzumab-dkst                   | Ogivri                | Q5114      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Trastuzumab-dttb                   | Ontruzant             | Q5112      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Trastuzumab-pkrb                   | Herzuma               | Q5113      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Trastuzumab-qyyp                   | Trazimera             | Q5116      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Trastuzumab-strf                   | Hercessi              | Q5146      | Medical Oncology - CHEMO | Primary - Biosimilar | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Tremelimumab-actl                  | Imjudo                | J9347      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Trilaciclib                        | Cosela                | J1448      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Triptorelin Pamoate                | Trelstar              | J3315      | Medical Oncology - CHEMO | Primary - LHRH       | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Valrubicin                         | Valstar               | J9357      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Vinblastine Sulfate                | Velban                | J9360      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S (P)                        | Y                        |                                                                                                        |
| Vincristine Sulfate                | Oncovin, Vincasar PFS | J9370      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S (P)                        | Y                        |                                                                                                        |
| Vinorelbine Tartrate               | Navelbine             | J9390      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S (P)                        | Y                        |                                                                                                        |
| Zanidatamab-hrii                   | Ziihera               | J9276      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        | New permanent HCPC Code: J9276 will replace NOC Codes: C9302 & J9999 for Ziihera, effective: 07/01/25  |
| Zenocutuzumab-zbco                 | Bizengri              | J9382      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        | New permanent HCPC Code: J9382 will replace NOC Codes: C9399 & J9999 for Bizengri, effective: 07/01/25 |
| Ziv-Aflibercept                    | Zaltrap               | J9400      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        |                                                                                                        |
| Zolbetuximab-clzb                  | Vyloy                 | J1326      | Medical Oncology - CHEMO | Primary              | INJECTABLE               | S                            | Y                        | New permanent HCPC Code: J1326 will replace NOC Codes: C9303 & J9999 for Vyloy, effective: 07/01/25    |
| Zoledronic Acid                    | Zoledronic Acid       | J3489      | Medical Oncology - SPORT | Supportive           | INJECTABLE               | S                            | Y                        |                                                                                                        |